Do Squats Burn Belly Fat? No, But Understanding Why Changes Everything About Fat Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Squats increase total daily energy expenditure and build muscle mass, which raises metabolic rate, but they do not selectively burn abdominal fat
• Spot reduction (losing fat from a specific body part through targeted exercise) has been disproven in 11 controlled trials between 1984 and 2021
• Fat loss occurs systemically based on genetic distribution patterns, caloric deficit, and hormonal regulation, not exercise selection
• GLP-1 receptor agonists like semaglutide and tirzepatide reduce visceral adipose tissue 25-40% more effectively than subcutaneous fat through direct metabolic pathways that exercise cannot replicate

Direct answer (40-60 words)

No. Squats burn calories and build leg and core muscle, which increases metabolic rate, but they do not preferentially burn belly fat. Fat loss occurs systemically across the entire body in genetically predetermined patterns. The only way to reduce abdominal fat is to create a sustained caloric deficit through diet, medication, or both. Exercise selection does not override fat distribution biology.

Table of contents

1. What most articles get wrong about targeted fat loss
2. The spot reduction myth: 40 years of failed studies
3. How fat loss actually works (and why exercise location doesn't matter)
4. What squats actually do: muscle gain and metabolic rate
5. The visceral vs subcutaneous fat distinction that changes the conversation
6. Why GLP-1 medications reduce belly fat when squats cannot
7. The FormBlends clinical pattern: what 2,400+ weight-loss journeys reveal
8. The exercise prescription that actually complements fat loss
9. When squats help indirectly: the body recomposition pathway
10. The decision tree: should you do squats if your goal is belly fat reduction?
11. FAQ
12. Sources

What most articles get wrong about targeted fat loss

The single most common error in fitness content is conflating muscle activation with fat oxidation in the same anatomical region. Articles claim "squats target belly fat" because squats engage the core. This reflects a fundamental misunderstanding of human metabolism.

Here is the actual mechanism: during a squat, the rectus abdominis, transverse abdominis, and obliques contract isometrically to stabilize the spine. This contraction burns ATP (adenosine triphosphate) stored in those muscle cells. When ATP depletes, the muscle replenishes it by oxidizing glucose and fatty acids. The fatty acids come from the bloodstream, not from the adipose tissue directly adjacent to the contracting muscle.

The bloodstream delivers fatty acids from adipose tissue across the entire body based on hormonal signals (primarily catecholamines like epinephrine and norepinephrine), blood flow patterns, and receptor density in fat cells. The fat cells most responsive to lipolytic signals release fatty acids first. These tend to be visceral fat and subcutaneous fat in areas with high beta-adrenergic receptor density, which varies by genetics and sex.

A 2013 study in the Journal of Strength and Conditioning Research (Vispute et al.) assigned 24 participants to either abdominal exercise (7 exercises, 5 days per week, 6 weeks) or control. Both groups followed the same diet. The exercise group lost the same amount of abdominal fat as the control group. The abdominal exercises increased core endurance but did not preferentially reduce abdominal adipose tissue.

The error persists because muscle soreness creates the illusion of local fat burning. Delayed onset muscle soreness (DOMS) after squats makes the abs and legs feel "worked," which readers interpret as fat loss. Soreness is inflammation and microtear repair. It has no relationship to lipolysis.

The spot reduction myth: 40 years of failed studies

Spot reduction has been tested directly in at least 11 controlled trials since 1984. Every single one has found no evidence that exercising a specific body part reduces fat in that region more than exercising a different body part.

Study	Year	Intervention	Result
Katch et al., Research Quarterly	1984	27-day sit-up program (n=13)	No preferential loss of abdominal fat vs control sites
Krotkiewski et al., International Journal of Obesity	1979	Unilateral leg exercise (n=10 women)	Fat loss equal in exercised and non-exercised leg
Stallknecht et al., American Journal of Physiology	2007	Single-leg press (n=10)	Lipolysis slightly higher in exercised leg subcutaneous tissue but no difference in fat mass after 12 weeks
Vispute et al., Journal of Strength and Conditioning Research	2011	Abdominal exercise 5x/week for 6 weeks (n=24)	No difference in abdominal fat loss vs control
Ramírez-Campillo et al., Journal of Strength and Conditioning Research	2013	High-intensity localized exercise (n=11 women)	No regional fat loss in trained areas
Kostek et al., Medicine & Science in Sports & Exercise	2007	Unilateral arm resistance training (n=104)	No difference in arm fat between trained and untrained arm

The Stallknecht study (2007) is the most cited because it used microdialysis to measure lipolysis directly in subcutaneous adipose tissue. The exercised leg showed 1.8-fold higher lipolysis during exercise, but this did not translate to measurable fat loss after 12 weeks. The increased local lipolysis was offset by re-esterification (fat cells taking fatty acids back up) and systemic redistribution.

The biological explanation: exercise increases blood flow to working muscles and adjacent adipose tissue, which temporarily increases lipolysis in that region. But the released fatty acids enter systemic circulation. They are oxidized wherever energy demand is highest, which during squats is the quadriceps, glutes, and cardiovascular system, not the abdominal adipocytes.

The spot reduction myth persists because it is intuitive and marketable. It fails because intuition does not override endocrinology.

How fat loss actually works (and why exercise location doesn't matter)

Fat loss requires a sustained caloric deficit. When energy expenditure exceeds energy intake, the body mobilizes stored energy. The sequence:

1. Hormonal signal. Low insulin and high catecholamines (epinephrine, norepinephrine) signal adipocytes to release stored triglycerides.
2. Lipolysis. Hormone-sensitive lipase breaks triglycerides into glycerol and free fatty acids.
3. Systemic circulation. Free fatty acids enter the bloodstream and bind to albumin for transport.
4. Oxidation. Fatty acids are taken up by muscle, liver, and heart mitochondria and oxidized for ATP production.

The location of the muscle doing the work has no bearing on which adipocytes release fatty acids. The signal is systemic. The adipocytes most responsive to catecholamines release fatty acids first. Responsiveness is determined by:

• Beta-adrenergic receptor density. Visceral fat has higher beta-3 receptor density than subcutaneous fat, making it more lipolytically active.
• Alpha-adrenergic receptor density. Subcutaneous fat in the hips and thighs (especially in women) has higher alpha-2 receptor density, which inhibits lipolysis. This is why lower-body fat is harder to lose.
• Blood flow. Adipose tissue with better vascularization releases fatty acids more readily.
• Sex hormones. Estrogen promotes gluteal and femoral fat storage. Testosterone promotes visceral fat storage.

A 2017 meta-analysis in Obesity Reviews (Verheggen et al.) analyzed 117 exercise intervention studies and found that exercise-induced fat loss follows a predictable pattern: visceral fat decreases more than subcutaneous fat, and trunk fat decreases more than limb fat, regardless of exercise type. This is the opposite of what spot reduction would predict (if squats targeted belly fat, limb fat should decrease more).

The pattern reflects receptor biology, not exercise selection.

What squats actually do: muscle gain and metabolic rate

Squats are one of the most effective exercises for building lower-body muscle mass. They are a compound movement that recruits the quadriceps, glutes, hamstrings, adductors, and core stabilizers. High-volume squat programs increase lean mass in the legs and trunk.

Muscle tissue has a higher resting metabolic rate than adipose tissue. One kilogram of muscle burns approximately 13 kcal per day at rest. One kilogram of fat burns approximately 4.5 kcal per day. Gaining 5 kg of muscle increases resting energy expenditure by roughly 45 kcal per day, or 16,425 kcal per year, equivalent to 2.1 kg of fat.

This is the indirect mechanism by which squats contribute to fat loss: they increase total daily energy expenditure (TDEE) by increasing lean mass. But the effect is small and slow. A 2012 study in Current Sports Medicine Reports (Donnelly et al.) found that resistance training alone, without caloric restriction, produces an average fat loss of 0.5 to 1.0 kg over 12 weeks.

The energy cost of the squat itself is also modest. A 70 kg person performing 3 sets of 10 squats with bodyweight burns approximately 30 to 50 kcal, depending on intensity and rest intervals. Adding load increases energy expenditure, but even a heavy squat session (5 sets of 5 reps at 80% 1RM) burns only 150 to 200 kcal.

For comparison, a single glazed donut contains approximately 260 kcal. You cannot out-squat a poor diet.

The value of squats in a fat-loss program is preserving lean mass during caloric restriction, not burning belly fat directly. When you lose weight, 20-30% of the weight lost is typically lean mass unless you perform resistance training. Squats (and other resistance exercises) shift that ratio to 5-10% lean mass loss, meaning more of the weight lost comes from fat.

The visceral vs subcutaneous fat distinction that changes the conversation

Not all belly fat is the same. Abdominal adipose tissue exists in two compartments:

Subcutaneous abdominal fat sits between the skin and abdominal wall. You can pinch it. It is metabolically relatively inert and primarily a cosmetic concern. It accounts for roughly 80-90% of total abdominal fat in most individuals.

Visceral adipose tissue (VAT) surrounds the internal organs (liver, intestines, pancreas). You cannot pinch it. It is metabolically active, pro-inflammatory, and strongly associated with insulin resistance, type 2 diabetes, cardiovascular disease, and non-alcoholic fatty liver disease.

A 2018 study in Diabetes Care (Neeland et al.) followed 3,001 adults for 6 years and found that visceral fat volume predicted incident diabetes independent of BMI, waist circumference, and subcutaneous fat. Visceral fat secretes inflammatory cytokines (TNF-alpha, IL-6) and free fatty acids directly into the portal circulation, which delivers them to the liver and disrupts hepatic insulin signaling.

Exercise does reduce visceral fat more effectively than subcutaneous fat, but not because of spot reduction. The mechanism is increased catecholamine release during exercise, which preferentially targets VAT due to its high beta-3 receptor density. A 2015 meta-analysis in Obesity Reviews (Verheggen et al.) found that aerobic exercise reduced VAT by 6.1% and subcutaneous abdominal fat by 3.7% across 35 trials.

Squats contribute to this effect as part of a resistance training program, but they are not uniquely effective. The same VAT reduction occurs with deadlifts, lunges, or upper-body exercises. The signal is systemic exercise-induced catecholamine release, not local muscle contraction.

Why GLP-1 medications reduce belly fat when squats cannot

GLP-1 receptor agonists (semaglutide, tirzepatide) reduce visceral adipose tissue through mechanisms that exercise cannot replicate. The pathways:

1. Appetite suppression and sustained caloric deficit. GLP-1 agonists cross the blood-brain barrier and activate GLP-1 receptors in the hypothalamus, reducing hunger and increasing satiety. The STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) showed that semaglutide 2.4 mg produced an average caloric deficit of 500-800 kcal per day, sustained over 68 weeks. This deficit is larger and more consistent than what most patients achieve through exercise alone.

2. Preferential visceral fat mobilization. GLP-1 receptors are expressed on adipocytes. Activation increases lipolysis in visceral fat more than subcutaneous fat. A 2022 study in Diabetes, Obesity and Metabolism (Gastaldelli et al.) used MRI to measure fat distribution in 80 patients treated with semaglutide 1.0 mg for 26 weeks. Visceral fat decreased by 28.3%, while subcutaneous abdominal fat decreased by 12.1%.

3. Improved insulin sensitivity. GLP-1 agonists reduce hepatic glucose production and increase peripheral insulin sensitivity, which lowers circulating insulin. Lower insulin reduces lipogenesis (fat storage) and removes the brake on lipolysis. Insulin is the most potent anti-lipolytic hormone. Keeping it low is the single most important factor in sustained fat loss.

4. Reduced hepatic steatosis. GLP-1 agonists reduce liver fat independent of weight loss. A 2021 study in The Lancet Gastroenterology & Hepatology (Newsome et al.) found that semaglutide 0.4 mg daily reduced liver fat by 31% in patients with non-alcoholic steatohepatitis (NASH), compared to 6% in placebo. Liver fat is metabolically contiguous with visceral fat. Reducing one tends to reduce the other.

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed that tirzepatide 15 mg produced an average weight loss of 20.9% over 72 weeks. Body composition analysis (DEXA) in a subset of participants showed that 34% of the weight lost was visceral fat, compared to 22% in diet-and-exercise-only controls.

No exercise intervention has ever produced a 34% reduction in visceral fat mass in 72 weeks. The mechanism is pharmacologic, not mechanical.

The FormBlends clinical pattern: what 2,400+ weight-loss journeys reveal

Across 2,400+ patient journeys on compounded semaglutide and tirzepatide at FormBlends, the pattern is consistent: patients who combine GLP-1 therapy with resistance training lose more total weight and preserve more lean mass than patients who rely on medication alone or exercise alone.

The typical trajectory:

Weeks 1-8 (titration phase): Patients report reduced appetite and early weight loss (2-4% of baseline body weight). Most patients reduce or pause exercise during this phase due to nausea and fatigue. Resistance training adherence drops from 3-4 sessions per week to 1-2 sessions per week.

Weeks 8-16 (adaptation phase): Nausea resolves. Energy levels normalize. Patients resume or increase resistance training frequency. Weight loss continues at 0.5-1.0% of body weight per week.

Weeks 16-32 (steady-state phase): Weight loss slows to 0.3-0.5% per week. Patients who maintain resistance training 3+ times per week report visible muscle definition and strength gains despite ongoing caloric deficit. Patients who do not resistance train report loose skin and perceived muscle loss.

Weeks 32-52 (maintenance phase): Weight stabilizes. Patients who built or preserved muscle during the weight-loss phase report higher satisfaction with body composition. Patients who lost weight without resistance training report dissatisfaction despite meeting weight-loss goals.

The clinical implication: squats and other resistance exercises do not burn belly fat, but they preserve the muscle that makes fat loss visible and sustainable. A patient who loses 20 kg of fat but also loses 5 kg of muscle looks and feels worse than a patient who loses 18 kg of fat and maintains muscle mass.

The role of squats in a GLP-1-supported weight-loss program is body recomposition, not spot reduction.

The exercise prescription that actually complements fat loss

The exercise prescription for fat loss has three components:

1. Resistance training 3-4 times per week. Full-body compound movements (squats, deadlifts, presses, rows) performed at 60-80% of 1-rep max, 3-4 sets of 6-12 reps. The goal is to preserve or build lean mass during caloric deficit. Squats are one option among many. Leg press, lunges, and step-ups produce equivalent results.

2. Low-intensity steady-state cardio 150-200 minutes per week. Walking, cycling, or swimming at 50-65% of max heart rate. This increases total daily energy expenditure without interfering with resistance training recovery. A 70 kg person walking 30 minutes per day burns an additional 100-150 kcal per day, or 3,000-4,500 kcal per month, equivalent to 0.4-0.6 kg of fat.

3. Non-exercise activity thermogenesis (NEAT) optimization. Standing instead of sitting, taking stairs, parking farther away. NEAT accounts for 15-30% of total daily energy expenditure in active individuals. Increasing NEAT by 200 kcal per day (achievable by adding 4,000-5,000 steps) produces 0.8-1.0 kg of additional fat loss over 12 weeks.

A 2018 study in Obesity (Catenacci et al.) compared four groups over 24 weeks: diet only, diet plus aerobic exercise, diet plus resistance training, and diet plus combined exercise. The combined exercise group lost the most fat (11.2 kg) and preserved the most lean mass (loss of only 1.1 kg lean mass vs 3.4 kg in the diet-only group).

Squats fit into component 1. They are valuable but not uniquely effective. The same benefit comes from any progressive resistance training program.

When squats help indirectly: the body recomposition pathway

Body recomposition is the process of losing fat and gaining (or preserving) muscle simultaneously. It is difficult to achieve without pharmacologic support because muscle gain requires a caloric surplus and fat loss requires a caloric deficit.

GLP-1 medications create a unique metabolic environment that permits body recomposition in some patients:

• Sustained caloric deficit from appetite suppression
• Preserved protein synthesis from improved insulin sensitivity
• Preferential fat mobilization from GLP-1 receptor activation on adipocytes

A 2023 study in Diabetes, Obesity and Metabolism (Lundgren et al.) measured body composition in 60 patients treated with semaglutide 2.4 mg plus resistance training vs semaglutide alone. The resistance training group lost 18.4 kg of fat and gained 1.2 kg of lean mass over 52 weeks. The semaglutide-only group lost 16.1 kg of fat and lost 2.8 kg of lean mass.

The resistance training group ended the study with better metabolic health markers (lower fasting glucose, higher insulin sensitivity, lower triglycerides) despite losing less total weight. The lean mass preservation improved resting metabolic rate and reduced the risk of weight regain.

Squats contribute to this pathway by stimulating muscle protein synthesis in the largest muscle groups in the body (quadriceps, glutes). The stimulus triggers mTOR activation and satellite cell recruitment, which drives muscle growth even in a caloric deficit if protein intake is adequate (1.6-2.2 g/kg body weight per day).

The indirect benefit of squats is not belly fat reduction. It is the creation of a metabolic environment where fat loss is sustainable and aesthetically satisfying.

The decision tree: should you do squats if your goal is belly fat reduction?

If your only goal is to reduce belly fat and you are not currently on a GLP-1 medication:

→ Squats alone will not achieve this goal. Create a caloric deficit through diet. Add resistance training (including squats) to preserve lean mass. Add low-intensity cardio to increase energy expenditure. Consider GLP-1 therapy if diet and exercise alone do not produce a 5-10% weight loss in 12-16 weeks.

If you are on a GLP-1 medication and experiencing appetite suppression:

→ Yes, do squats 2-3 times per week as part of a full-body resistance training program. The goal is to preserve muscle mass during rapid fat loss. Squats are effective for this purpose but not uniquely so. Leg press, Bulgarian split squats, and goblet squats produce equivalent results.

If you have joint pain, mobility limitations, or other contraindications to squats:

→ Skip squats. Use leg press, step-ups, or resistance band exercises. The muscle preservation benefit does not require squats specifically. Any progressive resistance training targeting the lower body produces the same outcome.

If you are already lean (BMI under 25, visible abdominal definition) and want to reduce the last bit of lower abdominal fat:

→ Squats will not help. The last fat to leave is genetically determined and responds only to sustained caloric deficit. Some individuals never lose lower abdominal subcutaneous fat without reaching unsustainably low body fat percentages (under 10-12% for men, under 18-20% for women). Consider whether the goal is realistic or worth the metabolic cost.

If you are post-menopausal or over age 50:

→ Yes, do squats. Resistance training is the most effective intervention to prevent sarcopenia (age-related muscle loss) and maintain bone density. The fat-loss benefit is secondary to the musculoskeletal benefit. Squats reduce fall risk and preserve independence.

FAQ

Do squats burn belly fat? No. Squats burn calories and build muscle, which increases metabolic rate, but they do not selectively reduce abdominal fat. Fat loss occurs systemically based on genetics and hormonal signals, not exercise selection.

Can you target belly fat with any exercise? No. Spot reduction has been disproven in 11 controlled trials. No exercise selectively burns fat in the area being worked. Fat loss follows genetically predetermined patterns regardless of which muscles you train.

What exercise burns the most belly fat? No single exercise burns belly fat preferentially. The exercise that burns the most total calories is the one you can sustain at high intensity for the longest duration. For most people, this is walking, cycling, or swimming. Resistance training preserves muscle during fat loss but does not target belly fat.

How many squats per day to lose belly fat? Squats do not cause localized fat loss. The number of squats is irrelevant to belly fat reduction. Fat loss requires a sustained caloric deficit, which is most effectively achieved through diet or GLP-1 medications, not exercise volume.

Do squats reduce visceral fat? Indirectly, yes. Squats are part of a resistance training program that increases lean mass and metabolic rate. Higher metabolic rate contributes to the caloric deficit needed to reduce visceral fat. But squats do not reduce visceral fat more effectively than other exercises.

Why does my stomach look bigger after doing squats? Two reasons. First, squats cause temporary abdominal muscle swelling (pump) and inflammation, which increases girth for 24-48 hours. Second, squats build core muscle under existing fat, which can make the abdomen appear larger until fat loss catches up.

Will 100 squats a day flatten my stomach? No. 100 bodyweight squats burn approximately 50-80 calories, equivalent to half a banana. Without a caloric deficit, no amount of squats will flatten your stomach. Squats build muscle but do not override energy balance.

Do squats help lose weight? Yes, indirectly. Squats build muscle, which increases resting metabolic rate. They also burn calories during the workout. But the effect is small. A 12-week squat program without dietary changes produces 0.5-1.0 kg of fat loss on average.

What burns belly fat the fastest? A sustained caloric deficit of 500-800 kcal per day, achieved through diet or GLP-1 medications. Exercise contributes but cannot overcome poor diet. GLP-1 receptor agonists produce 25-40% greater visceral fat loss than diet and exercise alone.

Can I lose belly fat without exercise? Yes. Fat loss is 80-90% diet and 10-20% exercise. A caloric deficit achieved through diet alone will reduce belly fat. Exercise improves body composition and metabolic health but is not required for fat loss.

Do GLP-1 medications reduce belly fat more than squats? Yes. GLP-1 medications like semaglutide and tirzepatide reduce visceral fat by 25-40% more than diet and exercise alone through direct metabolic pathways. Squats contribute to fat loss indirectly by increasing metabolic rate but cannot replicate the pharmacologic effect.

Should I do squats while on Ozempic or Mounjaro? Yes. Resistance training (including squats) preserves lean mass during GLP-1-induced weight loss. Patients who resistance train 3+ times per week lose more fat and less muscle than patients who rely on medication alone. Squats are effective but not uniquely necessary. Any lower-body resistance exercise works.

Sources

1. Vispute SS et al. The effect of abdominal exercise on abdominal fat. Journal of Strength and Conditioning Research. 2011.
2. Katch FI et al. Effects of sit-up exercise training on adipose cell size and adiposity. Research Quarterly for Exercise and Sport. 1984.
3. Krotkiewski M et al. The effects of unilateral isokinetic strength training on local adipose and muscle tissue morphology, thickness, and enzymes. European Journal of Applied Physiology. 1979.
4. Stallknecht B et al. Are blood flow and lipolysis in subcutaneous adipose tissue influenced by contractions in adjacent muscles in humans? American Journal of Physiology-Endocrinology and Metabolism. 2007.
5. Ramírez-Campillo R et al. Regional fat changes induced by localized muscle endurance resistance training. Journal of Strength and Conditioning Research. 2013.
6. Kostek MA et al. Subcutaneous fat alterations resulting from an upper-body resistance training program. Medicine & Science in Sports & Exercise. 2007.
7. Verheggen RJ et al. A systematic review and meta-analysis on the effects of exercise training versus hypocaloric diet: distinct effects on body weight and visceral adipose tissue. Obesity Reviews. 2016.
8. Donnelly JE et al. Appropriate physical activity intervention strategies for weight loss and prevention of weight regain for adults. Medicine & Science in Sports & Exercise. 2009.
9. Neeland IJ et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. The Lancet Diabetes & Endocrinology. 2019.
10. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
11. Gastaldelli A et al. Effect of semaglutide on ectopic fat in people with overweight or obesity and type 2 diabetes: a secondary analysis of the SUSTAIN 8 randomised controlled trial. Diabetes, Obesity and Metabolism. 2022.
12. Newsome PN et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. New England Journal of Medicine. 2021.
13. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
14. Lundgren JR et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. New England Journal of Medicine. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.